MedTrace Logo

Response to Immunotherapy in MMR-deficient Localized Colon Cancer

NCT05662527 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2024-08-13

No results posted yet for this study

Summary

The aim of this study is to evaluate the safety and efficacy of neoadjuvant treatment with pembrolizumab before colonic resection in patients with early-stage (I-III) deficient mismatch repair (dMMR) colon cancer (CC).

Conditions

Interventions

DRUG

Pembrolizumab

One dosage of 4mg/kg (maximum of 400mg)

Sponsors & Collaborators

  • Zealand University Hospital

    collaborator OTHER

  • Odense University Hospital

    collaborator OTHER

  • Vejle Hospital

    collaborator OTHER

  • Herlev and Gentofte Hospital

    collaborator OTHER

  • Bispebjerg Hospital

    collaborator OTHER

  • Aalborg University Hospital

    collaborator OTHER

  • Horsens Hospital

    collaborator OTHER

  • Randers Regional Hospital

    collaborator OTHER

  • Aarhus University Hospital

    collaborator OTHER

  • Camilla Qvortrup

    lead OTHER

Principal Investigators

  • Camilla Qvortrup, MD, PhD · Rigshospitalet, Denmark

  • Ismail Gögenur, Professor · Zealand University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-22
Primary Completion
2024-06-06
Completion
2024-06-06

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05662527 on ClinicalTrials.gov